HLA class II histocompatibility antigen, DP (HLA-DP)

HLA class II histocompatibility antigen, DP (HLA-DP) is a heterodimeric cell surface receptor consisting of an alpha (DPA1) and a beta (DPB1) chain. It belongs to the Major Histocompatibility Complex (MHC) class II family and is primarily expressed on professional antigen-presenting cells such as dendritic cells, B cells, and macrophages (UniProt P20036, P04440). The primary biological role of HLA-DP is to present processed exogenous peptides to CD4+ T-helper cells, a critical step in the initiation and regulation of the adaptive immune response (PubMed: 25308334). Genetic polymorphisms in the HLA-DP locus are significantly associated with the clearance or persistence of Hepatitis B virus and the risk of developing autoimmune disorders like sarcoidosis (PubMed: 19430480). In clinical transplantation, HLA-DP mismatches between donor and recipient are major determinants of graft-versus-host disease (GVHD) and the beneficial graft-versus-leukemia effect (PubMed: 24914137). Current therapeutic interventions involve broad immunosuppressants that modulate the downstream T-cell response, while emerging strategies focus on allele-specific targeting for cancer immunotherapy and transplant medicine.

Other names

MHC class II DPHLA-DPA1/HLA-DPB1 complexDP antigenHuman leukocyte antigen DPMajor histocompatibility complex, class II, DP

HLA-DP functions by binding exogenous peptides derived from pathogens or self-proteins and presenting them at the cell surface to CD4+ T-cell receptors (TCRs). This interaction, along with co-stimulatory signals, triggers T-cell differentiation and the subsequent adaptive immune response. Drugs targeting this pathway typically act by inhibiting T-cell activation (calcineurin inhibitors) or blocking the co-stimulatory signals required for the T-cell to respond to the HLA-peptide complex (CTLA-4 Ig analogs).